Cambridge Investment Research Advisors

Cambridge Investment Research Advisors’s GeneDx Holdings WGS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$259K	Buy	+3,775	New	+$215K	﹤0.01%	3330

Other funds holding WGS

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Legal Advantage Investments Los Altos Hills, California $285M AUM 18.63% 1-Year Est. Return

Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return

Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Grange Capital Beaverton, Oregon $108M AUM 18.7% 1-Year Est. Return

Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return

Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return

Cambridge Investment Research Advisors's WGS Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in GeneDx Holdings (WGS) in Q2 2026: 3,775 shares worth $259K. The stake represents ﹤0.01% of the portfolio and ranks #3330 among its holdings.

34 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

Cambridge Investment Research Advisors held 3,775 shares of GeneDx Holdings worth $259K as of Q2 2026.
GeneDx Holdings was a new Cambridge Investment Research Advisors position in Q2 2026.
GeneDx Holdings made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3330 holding.
34 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.